Third Rock Ventures Iv, L.P. Tango Therapeutics, Inc. (TNGX) insider trading activity

Third Rock Ventures Iv, L.P. is of Tango Therapeutics, Inc.. Currently has a direct ownership of 13.4 Million shares of TNGX, which is worth approximately $105 Million. The most recent transaction as insider was on Oct 23, 2025, when has been sold 477,401 shares (Common Stock) at a price of $10.15 per share, resulting in proceeds of $4,845,620. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 13.4M

20.6% 3M change

20.6% 12M change

Total Value Held $105 Million

Third Rock Ventures IV, L.P. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 23 2025	SELL Open market or private sale	$4,845,620 $10.15 p/Share	477,401 Reduced 3.44%	13,386,574 Common Stock
Sep 25 2025	SELL Open market or private sale	$4,010,000 $8.02 p/Share	500,000 Reduced 3.48%	13,863,975 Common Stock
Sep 16 2025	SELL Open market or private sale	$2,559,328 $7.04 p/Share	363,541 Reduced 2.47%	14,363,975 Common Stock
Sep 08 2025	SELL Open market or private sale	$608,671 $7.04 p/Share	86,459 Reduced 0.58%	14,727,516 Common Stock
Sep 05 2025	SELL Open market or private sale	$4,500,342 $7.0 p/Share	642,906 Reduced 4.16%	14,813,975 Common Stock
Aug 22 2025	SELL Open market or private sale	$2,115,358 $7.0 p/Share	302,194 Reduced 1.92%	15,456,881 Common Stock
Aug 19 2025	SELL Open market or private sale	$7,711,000 $7.01 p/Share	1,100,000 Reduced 6.52%	15,759,075 Common Stock
Sep 13 2024	SELL Open market or private sale	$709,722 $10.53 p/Share	67,400 Reduced 0.4%	16,859,075 Common Stock
Sep 05 2024	SELL Open market or private sale	$867,000 $11.56 p/Share	75,000 Reduced 0.44%	16,926,475 Common Stock
Aug 30 2024	SELL Open market or private sale	$2,030,000 $11.6 p/Share	175,000 Reduced 1.02%	17,001,475 Common Stock
Aug 27 2024	SELL Open market or private sale	$288,750 $11.55 p/Share	25,000 Reduced 0.15%	17,176,475 Common Stock
Aug 19 2024	SELL Open market or private sale	$1,513,500 $10.09 p/Share	150,000 Reduced 0.86%	17,201,475 Common Stock
Aug 16 2024	SELL Open market or private sale	$1,321,650 $9.79 p/Share	135,000 Reduced 0.77%	17,351,475 Common Stock
Aug 01 2024	SELL Open market or private sale	$392,000 $9.8 p/Share	40,000 Reduced 0.23%	17,486,475 Common Stock
Jul 31 2024	SELL Open market or private sale	$993,000 $9.93 p/Share	100,000 Reduced 0.57%	17,526,475 Common Stock
Jul 30 2024	SELL Open market or private sale	$931,000 $9.8 p/Share	95,000 Reduced 0.54%	17,626,475 Common Stock
Jul 26 2024	SELL Open market or private sale	$492,000 $9.84 p/Share	50,000 Reduced 0.28%	17,721,475 Common Stock
Jul 25 2024	SELL Open market or private sale	$992,912 $9.87 p/Share	100,599 Reduced 0.56%	17,771,475 Common Stock
Jul 24 2024	SELL Open market or private sale	$1,964,000 $9.82 p/Share	200,000 Reduced 1.11%	17,872,074 Common Stock
Jul 23 2024	SELL Open market or private sale	$1,223,750 $9.79 p/Share	125,000 Reduced 0.69%	18,072,074 Common Stock
Jul 22 2024	SELL Open market or private sale	$2,569,597 $9.78 p/Share	262,740 Reduced 1.42%	18,197,074 Common Stock
Jul 18 2024	SELL Open market or private sale	$1,878,516 $9.81 p/Share	191,490 Reduced 1.03%	18,459,814 Common Stock
Jul 17 2024	SELL Open market or private sale	$5,386,174 $9.79 p/Share	550,171 Reduced 2.87%	18,651,304 Common Stock
Feb 20 2024	SELL Open market or private sale	$1,950,000 $12.0 p/Share	162,500 Reduced 0.84%	19,201,475 Common Stock

Also insider at

RVMD

Revolution Medicines, Inc. Healthcare

> 10% Shareholder

FULC

Fulcrum Therapeutics, Inc. Healthcare

> 10% Shareholder

MGTA

Magenta Therapeutics, Inc. Healthcare

> 10% Shareholder

MAZE

Maze Therapeutics, Inc.

TRV